Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.


Journal

Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420

Informations de publication

Date de publication:
01 09 2022
Historique:
pubmed: 22 3 2022
medline: 9 9 2022
entrez: 21 3 2022
Statut: ppublish

Résumé

Intratumoral heterogeneity is crucially involved in metastasis, resistance to therapy, and cancer relapse. Amplifications of the proto-oncogene MYC display notable heterogeneity at the single-cell level and are associated with a particularly dismal prognosis in high-risk medulloblastomas (MBs). The aim of this study was to establish the relevance of interclonal cross-talk between MYC-driven and non-MYC-driven MB cells. We used fluorescence in situ hybridization, single-cell transcriptomics, and immunohistochemistry, in vitro isogenic cell models, non-targeted proteomics, mass spectrometry-based metabolite quantification, HUVECs tube formation assay, and orthotopic in vivo experiments to investigate interclonal cross-talk in MB. We found that the release of lactate dehydrogenase A (LDHA) from MYC-driven cells facilitates metastatic seeding and outgrowth, while secretion of dickkopf WNT signaling pathway inhibitor 3 from non-MYC-driven cells promotes tumor angiogenesis. This tumor-supporting interaction between both subclones was abrogated by targeting the secretome through pharmacological and genetic inhibition of LDHA, which significantly suppressed tumor cell migration. Our study reveals the functional relevance of clonal diversity and highlights the therapeutic potential of targeting the secretome to interrupt interclonal communication and progression in high-risk MB.

Sections du résumé

BACKGROUND
Intratumoral heterogeneity is crucially involved in metastasis, resistance to therapy, and cancer relapse. Amplifications of the proto-oncogene MYC display notable heterogeneity at the single-cell level and are associated with a particularly dismal prognosis in high-risk medulloblastomas (MBs). The aim of this study was to establish the relevance of interclonal cross-talk between MYC-driven and non-MYC-driven MB cells.
METHODS
We used fluorescence in situ hybridization, single-cell transcriptomics, and immunohistochemistry, in vitro isogenic cell models, non-targeted proteomics, mass spectrometry-based metabolite quantification, HUVECs tube formation assay, and orthotopic in vivo experiments to investigate interclonal cross-talk in MB.
RESULTS
We found that the release of lactate dehydrogenase A (LDHA) from MYC-driven cells facilitates metastatic seeding and outgrowth, while secretion of dickkopf WNT signaling pathway inhibitor 3 from non-MYC-driven cells promotes tumor angiogenesis. This tumor-supporting interaction between both subclones was abrogated by targeting the secretome through pharmacological and genetic inhibition of LDHA, which significantly suppressed tumor cell migration.
CONCLUSION
Our study reveals the functional relevance of clonal diversity and highlights the therapeutic potential of targeting the secretome to interrupt interclonal communication and progression in high-risk MB.

Identifiants

pubmed: 35307743
pii: 6551011
doi: 10.1093/neuonc/noac068
pmc: PMC9435486
doi:

Substances chimiques

Proto-Oncogene Proteins c-myc 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1509-1523

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Neuro Oncol. 2021 Apr 12;23(4):527-529
pubmed: 33749759
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
Arch Biochem Biophys. 1973 Oct;158(2):681-6
pubmed: 4782528
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Nature. 2013 Aug 1;500(7460):39-44
pubmed: 23842495
Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
pubmed: 12516034
Int J Cancer. 2008 Apr 1;122(7):1539-47
pubmed: 18033687
Cancer Cell. 2016 Apr 11;29(4):440-451
pubmed: 27070699
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
Expert Rev Proteomics. 2012 Jun;9(3):337-45
pubmed: 22809211
Cancer Cell. 2018 Sep 10;34(3):396-410.e8
pubmed: 30205044
Neuro Oncol. 2021 Apr 12;23(4):586-598
pubmed: 33175161
Neuro Oncol. 2022 Feb 1;24(2):273-286
pubmed: 34077540
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Cell. 2018 Sep 10;34(3):379-395.e7
pubmed: 30205043
Nephrol Dial Transplant. 2019 Jan 1;34(1):49-62
pubmed: 29726981
Methods Mol Biol. 2021;2228:293-306
pubmed: 33950499
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Acta Neuropathol. 2015 Mar;129(3):449-57
pubmed: 25689980
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Nature. 2015 Jan 29;517(7536):583-8
pubmed: 25494202
Proteomics. 2009 Nov;9(21):4997-5000
pubmed: 19810033
Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15605-10
pubmed: 18832152
Nat Methods. 2015 Dec;12(12):1143-9
pubmed: 26501517
Cancer Cell. 2019 Sep 16;36(3):302-318.e7
pubmed: 31474569
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
J Clin Endocrinol Metab. 2014 Oct;99(10):3903-11
pubmed: 25014000
Nature. 2003 Aug 21;424(6951):870-2
pubmed: 12931155
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Cancer Metab. 2013 Sep 06;1(1):19
pubmed: 24280423
Cancer Cell. 2020 Apr 13;37(4):471-484
pubmed: 32289271
Mol Ther. 2008 Apr;16(4):698-706
pubmed: 18362927
Nature. 2012 Aug 2;488(7409):43-8
pubmed: 22722829
Bioinformatics. 2019 Sep 15;35(18):3357-3364
pubmed: 30715209
Nat Commun. 2019 Jan 10;10(1):130
pubmed: 30631061
Arch Pathol Lab Med. 2002 May;126(5):540-4
pubmed: 11958658
Cancer Res. 2019 Apr 15;79(8):1967-1980
pubmed: 30862721
Nat Genet. 2017 May;49(5):780-788
pubmed: 28394352
J Clin Oncol. 2009 Apr 1;27(10):1627-36
pubmed: 19255330
Cell Stem Cell. 2010 Nov 5;7(5):618-30
pubmed: 20888316
Nature. 2019 Aug;572(7767):74-79
pubmed: 31341285
Brain Pathol. 2016 Jan;26(1):3-17
pubmed: 26269128
Clin Cancer Res. 2014 Feb 15;20(4):912-25
pubmed: 24297863
Nat Commun. 2019 Dec 20;10(1):5829
pubmed: 31863004
Biochem Biophys Res Commun. 1990 Apr 30;168(2):677-82
pubmed: 2334430
Cell. 2017 Oct 5;171(2):358-371.e9
pubmed: 28985563

Auteurs

Nan Qin (N)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Eunice Paisana (E)

Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

Maike Langini (M)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.
Institute for Molecular Medicine I, Heinrich Heine University, University Hospital Düsseldorf , Düsseldorf, Germany.

Daniel Picard (D)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Bastian Malzkorn (B)

Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Carlos Custódia (C)

Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

Rita Cascão (R)

Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

Frauke-Dorothee Meyer (FD)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Lena Blümel (L)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Sarah Göbbels (S)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Kübra Taban (K)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Jasmin Bartl (J)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Nicole Bechmann (N)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, and Technical University Dresden , Dresden, Germany.
Department of Medicine III, University Hospital Carl Gustav Carus, Technical University Dresden , Dresden, Germany.
Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
German Center for Diabetes Research, München-Neuherberg, Germany.

Catleen Conrad (C)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, and Technical University Dresden , Dresden, Germany.
Department of Medicine III, University Hospital Carl Gustav Carus, Technical University Dresden , Dresden, Germany.

Jan Gravemeyer (J)

Translational Skin Cancer Research, University Duisburg-Essen, Essen, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jürgen C Becker (JC)

Translational Skin Cancer Research, University Duisburg-Essen, Essen, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Anja Stefanski (A)

Molecular Proteomics Laboratory, Biomedical Research Center (BMFZ), Heinrich Heine University, Medical Faculty, Düsseldorf, Germany.

Stéphanie Puget (S)

Department of Pediatric Neurosurgery, Necker Hospital, Paris Descartes University, Paris, France.

João T Barata (JT)

Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

Kai Stühler (K)

Institute for Molecular Medicine I, Heinrich Heine University, University Hospital Düsseldorf , Düsseldorf, Germany.
Molecular Proteomics Laboratory, Biomedical Research Center (BMFZ), Heinrich Heine University, Medical Faculty, Düsseldorf, Germany.

Ute Fischer (U)

Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.

Jörg Felsberg (J)

Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Olivier Ayrault (O)

Institut Curie, PSL Research University, Université Paris Sud, Université Paris-Saclay, Orsay, France.

Guido Reifenberger (G)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Arndt Borkhardt (A)

Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.

Graeme Eisenhofer (G)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, and Technical University Dresden , Dresden, Germany.
Department of Medicine III, University Hospital Carl Gustav Carus, Technical University Dresden , Dresden, Germany.

Claudia C Faria (CC)

Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Department of Neurosurgery, Hospital Santa Maria, Centro Hospitalar Lisboa Norte, EPE, Lisbon, Portugal.

Marc Remke (M)

German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf , Düsseldorf, Germany.
Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
Institute of Neuropathology, Medical Faculty, HHU, UKD, Düsseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH